UCB (UCBJF) Stock Price, News & Analysis

Company Overview

UCB S.A. is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline. Notable medicines associated with UCB include Cimzia (certolizumab pegol), used in inflammatory and autoimmune conditions, and antiepileptic agents such as levetiracetam (Keppra) and brivaracetam (Briviact). UCB invests in R&D across discovery, clinical development and lifecycle management and frequently collaborates with academic groups, biotechnology partners and contract research organizations to advance novel mechanisms and delivery approaches.

Headquartered in Brussels, UCB operates internationally, serving patients and healthcare systems across Europe, North America, Asia-Pacific and other regions. The company is managed through an executive leadership team and overseen by a board of directors; it also maintains manufacturing, regulatory and commercial functions to support global product supply and market access. UCB’s strategic priorities emphasize scientific innovation, targeted therapeutic development and partnerships aimed at addressing unmet medical needs in neurology and immunology.

Key Stats

• Today's Range: $302.48 to $307.59
• 50-Day Range: $270.35 to $321.05
• 52-Week Range: $194.76 to $345.39
• Volume: 172 shs
• Average Volume: 708 shs
• Market Capitalization: $57.18 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

UCB Stock Analysis - MarketRank™

UCB scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

UCB has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

UCB has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 49.58%

Earnings Growth

Earnings for UCB are expected to grow by 49.58% in the coming year, from $4.72 to $7.06 per share.

Price to Book Value per Share Ratio

UCB has a P/B Ratio of 6.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.37% of the float of UCB has been sold short.

Short Interest Ratio / Days to Cover

UCB has a short interest ratio ("days to cover") of 848.01, which indicates bearish sentiment.

Change versus previous month

Short interest in UCB has recently decreased by 37.17%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

UCB does not currently pay a dividend.

Dividend Growth

UCB does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

UCB has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for UCB this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added UCB to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, UCB insiders have not sold or bought any company stock.

Percentage Held by Institutions

UCB has minimal institutional ownership at this time.

Company Calendar

• Today: 7/02/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:UCBJF
• CIK: 1290640
• Web: www.ucb.com
• Phone: (322) 559-9999
• Fax: 32-2559-9900
• Employees: 9,083
• Year Founded: 1928

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 1.19
• Quick Ratio: 0.78

Sales & Book Value

• Annual Sales: $5.27 billion
• Price / Sales: 10.95
• Cash Flow: $13.11 per share
• Price / Cash Flow: 23.28
• Book Value: $50.52 per share
• Price / Book: 6.04

Miscellaneous

• Outstanding Shares: 189,020,000
• Free Float: N/A
• Market Cap: $57.70 billion
• Optionable: Not Optionable
• Beta: 0.47